These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 31951328)

  • 1. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.
    Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y
    Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic onset juvenile idiopathic arthritis: a single center experience.
    Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
    Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab for juvenile idiopathic arthritis: a single-center case series.
    Yazılıtaş F; Özdel S; Şimşek D; Aydoğ Ö; Çakıcı EK; Can GG; Güngör T; Bülbül M
    Sao Paulo Med J; 2019; 137(6):517-522. PubMed ID: 32159638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab for treating juvenile idiopathic arthritis.
    Turnier JL; Brunner HI
    Expert Opin Biol Ther; 2016; 16(4):559-66. PubMed ID: 26848760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.
    Grönlund MM; Remes-Pakarinen T; Kröger L; Markula-Patjas K; Backström M; Putto-Laurila A; Aalto K; Vähäsalo P
    Rheumatology (Oxford); 2020 Apr; 59(4):732-741. PubMed ID: 31359057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
    Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
    Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
    Brunner HI; Ruperto N; Zuber Z; Keane C; Harari O; Kenwright A; Lu P; Cuttica R; Keltsev V; Xavier RM; Calvo I; Nikishina I; Rubio-Pérez N; Alexeeva E; Chasnyk V; Horneff G; Opoka-Winiarska V; Quartier P; Silva CA; Silverman E; Spindler A; Baildam E; Gámir ML; Martin A; Rietschel C; Siri D; Smolewska E; Lovell D; Martini A; De Benedetti F; ;
    Ann Rheum Dis; 2015 Jun; 74(6):1110-7. PubMed ID: 24834925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
    Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis.
    Batu ED; Sönmez HE; Gülhan B; Arıcı ZS; Topaloğlu R; Bilginer Y
    Turk J Pediatr; 2017; 59(1):6-12. PubMed ID: 29168357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis.
    Brunner HI; Chen C; Bovis F; De Benedetti F; Espada G; Joos R; Akikusa J; Chaitow J; Boteanu AL; Kimura Y; Rietschel C; Siri D; Smolewska E; Schmeling H; Brown DE; Martini A; Lovell DJ; Huang B; Ruperto N;
    Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1264-1274. PubMed ID: 32702212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
    Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
    Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biotherapy in juvenile idiopathic arthritis Moroccan patients: a single-center experience.
    Bouayed K; Hamraoui D; Mikou N; Sakhi A; Hilmi W
    Pan Afr Med J; 2022; 41():135. PubMed ID: 35519160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tocilizumab for refractory systemic juvenile idiopathic arthritis].
    Lai JM; Wu FQ; Zhou ZX; Kang M; Huang XL; Su GX; Li SN; Zhu J; Wang XN
    Zhonghua Er Ke Za Zhi; 2017 Nov; 55(11):830-834. PubMed ID: 29141313
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
    Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
    Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
    De Benedetti F; Brunner HI; Ruperto N; Kenwright A; Wright S; Calvo I; Cuttica R; Ravelli A; Schneider R; Woo P; Wouters C; Xavier R; Zemel L; Baildam E; Burgos-Vargas R; Dolezalova P; Garay SM; Merino R; Joos R; Grom A; Wulffraat N; Zuber Z; Zulian F; Lovell D; Martini A; ;
    N Engl J Med; 2012 Dec; 367(25):2385-95. PubMed ID: 23252525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
    Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
    J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.
    Brunner HI; Ruperto N; Ramanan AV; Horneff G; Minden K; Calvo Penades I; Alexeeva E; Cleary G; Stern SM; Kone-Paut I; Maldonado Velázquez MDR; Rabinovich CE; Remesal A; Silva CA; Nikishina I; Zucchetto M; Brockwell L; Gordon O; Nagel S; De Benedetti F;
    Rheumatology (Oxford); 2024 Sep; 63(9):2535-2546. PubMed ID: 38552315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
    Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
    J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.